TRIF plays critical role in bioscience research, tech transfer at state universitiesContinue reading
Category Archives: AZBio News
UArizona Partners with State to Provide COVID-19 Antibody Test
The state investment will allow UArizona to test 250,000 of Arizona’s front-line workforce.Continue reading
UArizona Health Sciences ‘Wellness Wednesdays’ Webinars Offer Community Connection during Social Distancing
The free, interactive 30-minute lunchtime webinars feature University of Arizona Health Sciences-affiliated faculty and staff members as presenters and provide information and tools to help support individuals as they navigate the new reality of Arizona’s stay-at-home orders in response to the COVID-19 pandemic.
Continue reading
Why AZBio’s CEO is Hopeful
In this difficult time, there is beauty and evidence all around us that inspires hope.Continue reading
STERIS Announces Decontamination Solution for Respiratory Masks
- U.S. FDA Grants Emergency Use Authorization
- Solution Leverages Existing Equipment to Allow Hospitals to Decontaminate On-site
Gilead CEO Provides an Open Letter on Remdesivir Development
This is the third Open Letter published by Gilead Chairman and CEO Daniel O’Day to update the public on the remdesivir development process.
Treasury and Federal Reserve Board Announce New and Expanded Lending Programs to Provide up to $2.3 Trillion in Financing
WASHINGTON – Pursuant to section 13(3) of the Federal Reserve Act, U.S. Treasury Secretary Steven T. Mnuchin today approved the establishment of a Main Street Business Lending Program and a Municipal Liquidity Facility to support the flow of credit to American workers, businesses, States, counties, and cities impacted by the coronavirus pandemic.
Small and medium-sized businesses, through no fault of their own, have faced severe financial strain from widespread closures and liquidity pressures in the financial system. Using funds appropriated under the CARES Act, Treasury will make a $75 billion equity investment in a special purpose vehicle established to implement the Main Street Business Lending Program. This investment will enable up to $600 billion in new financing for businesses with up to 10,000 employees or $2.5 billion in 2019 annual revenues.Continue reading
Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Glogal COVID-19 Vaccine Development
- Pfizer and BioNTech to jointly develop COVID-19 vaccine, initially in the United States and Europe, and scale-up manufacturing capacity to support global supply
- Potential to supply millions of vaccine doses by the end of 2020 subject to technical success of the development program and approval by regulatory authorities, and then rapidly scale up capacity to produce hundreds of millions of doses in 2021
- BioNTech will contribute multiple mRNA vaccine candidates as part of its BNT162 COVID-19 vaccine program, which are expected to enter human testing in April 2020
- Pfizer will contribute its leading global vaccine clinical research and development, regulatory, manufacturing and distribution infrastructure and capabilities
- BioNTech will receive an upfront payment of $185 million, including an equity investment of approximately $113 million, and be eligible to receive future milestone payments of up to $563 million for a potential total consideration of $748 million
Pfizer Advances Battle Against COVID-19 on Multiple Fronts
-
- Anti-viral compounds show activity against SARS-CoV-2 in preclinical screening
- Pfizer and BioNTech enter into collaboration agreement to co-develop potential COVID-19 vaccine Company shares additional data and analysis of azithromycin
- Launch of two new studies to provide insights on the interaction between S. pneumoniae and SARS-CoV-2
- Pfizer explores studies of JAK inhibitor tofacitinib in patients with COVID-19-related pneumonia
Kauffman Fellows and Venture Capitalists “Meet” to Discuss COVID-19 Impacts
Over 250 Kauffman Fellows and VCs from all continents held a two day Zoom Conference last week to examine the effect of COVID on investment practices. The Kauffman Fellows Program is a network of over 500 VCs and entrepreneurs. Our Dr. Patricia Beckmann, a Kauffman Fellow, participated in the brainstorming session to encourage sharing and best practices. Continue reading